MGMT and central nervous system cancer: In high-grade gliomas, epigenetic silencing of MGMT by promoter methylation enhances the sensitivity of tumor cells to alkylating drugs such as temozolomide or nitrosoureas and is, therefore, considered a predictive marker for the clinical response to alkylating chemotherapy [26,27,28].